文献速递流行病学与生物统计临床试验与 GCP

简单随机化在较小规模试验中未能防止偏倚

Simple randomization did not protect against bias in smaller trials.
PubMed 文献 · J Clin Epidemiol · 2017-02-28

研究重新分析国际卒中试验(IST)与冠脉搭桥体外或体外循环再血管化研究(CORONARY)两项已发表的多中心大型简单随机试验,并对不同样本量随机抽样重复分析1000次,同时进行蒙特卡洛模拟。结果显示,样本量至少1000例时随机化可消除组间随机差异、效应估计偏倚极小;样本量较小时则观察到明显偏倚,完全随机化试验纳入少量参与者所得结论可能不可靠。

要点

  • 样本量至少1000例时,随机化可消除治疗组间随机差异,效应估计偏倚极小。
  • 样本量较小时观察到明显偏倚,完全随机化试验纳入少量参与者所得结论可能不可靠。
  • 作者认为此种情况下分配治疗可考虑最小化或区组等替代方法。

核心结论

  • 完全随机化试验仅纳入少量参与者时所得结论可能不可靠;样本量较小时可观察到明显偏倚。
  • 作者认为此种情况下可考虑最小化或区组等替代方法进行治疗分配。

研究设计与样本

  • 重新分析两项已发表的多中心、大型、简单随机试验:国际卒中试验(IST)和冠脉搭桥体外或体外循环再血管化研究(CORONARY)。
  • 按不同样本量随机抽样,对研究者原先报告的分析重复1000次,并评估各治疗组间协变量平衡。
  • 另进行一系列随机化试验的蒙特卡洛模拟以补充上述分析。

主要发现

  • 纳入至少1000例参与者时,随机化可消除治疗组间随机差异,从而使效应估计偏倚极小。
  • 样本量较小时,观察到明显偏倚。
  • 在简短综述中显示,最高影响因子医学期刊发表的3期试验中有41.5%达到这样的入组样本量。
  • 估计了阿司匹林和肝素对卒中后30天死亡或依赖的影响(IST)。
  • 估计了体外循环冠脉搭桥对30天死亡、非致死性卒中、非致死性心肌梗死或需透析的新发肾衰竭复合主要结局的影响(CORONARY)。

关键数值与推荐

  • 随机化消除治疗组间随机差异所需的最低样本量为至少1000例参与者。
  • 最高影响因子医学期刊发表的3期试验中41.5%达到该入组样本量。

临床怎么用

  • 作者认为,完全随机化试验仅纳入少量参与者时所得结论可能不可靠,此种情况下可考虑最小化或区组等替代方法进行治疗分配。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: By removing systematic differences across treatment groups, simple randomization is assumed to protect against bias. However, random differences may remain if the sample size is insufficiently large. We sought to determine the minimal sample size required to eliminate random differences, thereby allowing an unbiased estimation of the treatment effect. STUDY DESIGN AND SETTING: We reanalyzed two published multicenter, large, and simple trials: the International Stroke Trial (IST) and the Coronary Artery Bypass Grafting (CABG) Off- or On-Pump Revascularization Study (CORONARY). We reiterated 1,000 times the analysis originally reported by the investigators in random samples of varying size. We measured the covariates balance across the treatment arms. We estimated the effect of aspirin and heparin on death or dependency at 30 days after stroke (IST), and the effect of off-pump CABG on a composite primary outcome of death, nonfatal stroke, nonfatal myocardial infarction, or new renal failure requiring dialysis at 30 days (CORONARY). In addition, we conducted a series of Monte Carlo simulations of randomized trials to supplement these analyses. RESULTS: Randomization removes random differences between treatment groups when including at least 1,000 participants, thereby resulting in minimal bias in effects estimation. Later, substantial bias is observed. In a short review, we show such an enrollment is achieved in 41.5% of phase 3 trials published in the highest impact medical journals. CONCLUSIONS: Conclusions drawn from completely randomized trials enrolling a few participants may not be reliable. In these circumstances, alternatives such as minimization or blocking should be considered for allocating the treatment.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Nguyen TL, Collins GS, Lamy A, et al. Simple randomization did not protect against bias in smaller trials. J Clin Epidemiol. 2017. PMID: 28257927. doi:10.1016/j.jclinepi.2017.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。